GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for GSK
55.14
-0.16 (-0.29%)
After Hours: 55.15 +0.01 (0.02%)
Apr 23, 5:16PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 54.96 - 55.52
52 week 48.30 - 56.73
Open 55.50
Vol / Avg. 2.25M/2.41M
Mkt cap 133.91B
P/E 14.75
Div/yield 0.75/4.48
EPS 3.74
Shares 2.43B
Beta 0.58
Inst. own 10%
May 7, 2014
GlaxoSmithKline PLC Annual General Meeting - 9:30AM EDT - Add to calendar
Apr 30, 2014
Q1 2014 GlaxoSmithKline PLC Earnings Release - 3:00AM EDT - Add to calendar
Mar 4, 2014
GlaxoSmithKline at Cowen Health Care Conference
Mar 4, 2014
GlaxoSmithKline at Credit Suisse Healthcare Conference
Feb 24, 2014
GlaxoSmithKline at Citi Global Healthcare Conference
Feb 5, 2014
Q4 2013 GlaxoSmithKline Earnings Conference Call
Feb 5, 2014
Q4 2013 GlaxoSmithKline PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 36.27% 21.23%
Operating margin 39.01% 27.58%
EBITD margin - 35.58%
Return on average assets 24.15% 13.47%
Return on average equity 152.20% 84.96%
Employees 99,488 -
CDP Score - 98 A

Address

C8 Gsk House, 980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 48
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 49
Bio & Compensation  - Reuters
Moncef Slaoui Chairman - Research & Development, Executive Director
Age: 53
Bio & Compensation  - Reuters
Deirdre P. Connelly President - North American Pharmaceuticals
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Marc Dunoyer Chairman - GSK Japan, Global Head - GSK Rare Diseases
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe & EMAP
Age: 47
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Christophe Weber President - Vaccines
Bio & Compensation  - Reuters